See Recent Shionogi-Sponsored Congress Presentations

Congresses

As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.

The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Select a congress event or filter to view available congress presentations.

  • All
  • AAN
  • ESPID
  • APCCMI
  • ASCP
  • ASM Microbe
  • AVG and IMRP
  • CROI
  • ESCMID
  • GSA
  • IAS
  • IDWeek
  • ISIRV
  • NACFC
  • SCCM
  • All
  • 2024
  • 2025
  • 2026
  • All
  • Amyotrophic Lateral Sclerosis (ALS)
  • COVID-19
  • Gram-negative infection
  • Respiratory Syncytial Virus (RSV)
  • All
  • Cefiderocol
  • Edaravone
  • Ensitrelvir
  • S-337395
  • S-892216
  • Xeruborbactam
  • All
  • Oral presentation
  • Poster presentation

You Are Viewing Presentations

ESCMID 2025
Cefiderocol

Cefiderocol activity against resistant bacteria from patients with ventilator-associated pneumonia from European and US hospitals

View/Download Presentation
ESCMID 2026
Cefiderocol

Cefiderocol demonstrated potent in vitro activity against carbapenem-resistant non-fermenting gram-negative bacteria, including WHO priority pathogens, in China

View/Download Presentation
ESCMID 2026
Cefiderocol

Cefiderocol in clinical practice for bone and joint infections: insights from the PROVE study

View/Download Presentation
IDWeek 2025
Cefiderocol

Cefiderocol remains active against US clinical isolates of Stenotrophomonas maltophilia non-susceptible to comparator agents: results from the SENTRY antimicrobial surveillance program (2020–2024)

View/Download Presentation
IDWeek 2024
Cefiderocol

Cefiderocol remains highly active against carbapenemase-producing Enterobacterales

View/Download Presentation
IDWeek 2024
Cefiderocol

Cefiderocol retains in vitro activity against Enterobacterales non-susceptible to β-lactam-β-lactamase inhibitor combinations

View/Download Presentation

You Are Viewing Congress Locations